Back to search results

Lattice Radiotherapy for Bulky Tumors

This study is testing a type of radiation therapy called lattice radiotherapy (LRT) for people with large (bulky) solid tumors, including metastatic cancer. The goal is to see if LRT works better than standard radiation to shrink these tumors. You might be able to join if you are 18 or older, have a solid tumor that needs radiation, and your tumor can be measured and treated with LRT. The researchers will look at how much the tumors shrink after treatment and any side effects you might experience. The study is currently recruiting participants.

Study design
This is a single-center study, meaning it's happening at one location, and it's a single-arm study, so everyone gets the same treatment. It plans to enroll 37 patients.
What's involved
You would receive 5 treatments of lattice radiation therapy every other day. You would have follow-up visits to check for side effects at day 5, day 15, day 30, and day 60 after your treatment.
Compensation
Not stated in the trial record.
Follow-up
Your tumor response will be checked at 60 days after treatment, and side effects will be monitored for up to 60 days post-treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06416007

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Recruiting
PHASE2Ages 18+InterventionalTreatment
University of Cincinnati
~37 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Lattice therapy (LRT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Response Rate
Measured over 60 days post treatment
+1 more outcome measured

Conditions

Cancer
Metastatic Cancer
Locally Advanced
Locally Advanced Solid Tumor
Locally Advanced Carcinoma

Explore related trials

Solid Neoplasm

NCT06416007

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Cincinnati Medical Center

    Cincinnati, Ohiono site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

UCCC Clinical Trials Office
[email protected]
513-584-7698
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Solid tumor malignancy with a clinical indication for radiation
Patients must have measurable disease
Target lesion(s) which are amenable to lattice therapy plan
When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
Age ≥18 years.
ECOG Performance status ≤2
Life expectancy greater than 3 months
Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
Ability to understand and the willingness to sign a written informed consent document

Exclusion

Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
Patients with a history of conditions which predispose them to increased radiation toxicity
Patients with known contraindications to radiation therapy
Patients with uncontrolled intercurrent illness
Pregnant women

What this trial measures

  • Overall Response Rate60 days post treatment

    To evaluate the efficacy of lattice therapy in patients with bulky tumors, as measured by objective response rate (ORR) at 60 days post-treatment.

  • Adverse EventsUp to 60 days post-treatment

    To characterize the safety profile and adverse events (AEs) of lattice therapy.